1 |
Kalis MM, Huff NA. Oxcarbazepine, an antiepileptic agent. Clin Ther 2001;23:680-700.
DOI
|
2 |
Dam M, Ekberg R, Loyning Y, Waltimo O, Jakobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989;3: 70-6.
DOI
|
3 |
Dam M. Practical aspects of oxcarbazepine treatment. Epilepsia 1994; 35 Suppl 3:S23-5.
DOI
|
4 |
Dichter MA, Brodie MJ. New antiepileptic drugs. N Engl J Med 1996;3 34:1583-90.
DOI
|
5 |
Knowles SR, Shapiro LE, Shear NH. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf 1999; 21:489-501.
DOI
|
6 |
Hitiris N, Brodie MJ. Modern antiepileptic drugs: guidelines and beyond. Curr Opin Neurol 2006;19:175-80.
DOI
|
7 |
Horga de la Parte JF, Horga A. Oxcarbazepine in the treatment of epilepsy. A review and update. Rev Neurol 2006;42:95-113.
DOI
|
8 |
Milia A, Pilia G, Mascia MG, Moller J, Cocco E, Marrosu MG. Oxcarbazepine-induced leukopenia. J Neuropsychiatry Clin Neurosci 2008; 20:502-3.
DOI
|
9 |
Calamaras MR, Stowe ZN, Newport DJ. Pancytopenia associated with the introduction of oxcarbazepine. J Clin Psychopharmacol 2007;27: 217-8.
DOI
|
10 |
Son YR, Son YR, Kim YS, Kim YS, Chu K, Chu K, et al. Oxcarbazepine induced leukopenia. J Korean Epilepsy Soc 2013;17:22-3.
|
11 |
Serdaroglu G, Kurul S, Tutuncuoglu S, Dirik E, Sarioglu B. Oxcarbazepine in the treatment of childhood epilepsy. Pediatr Neurol 2003;28: 37-41.
DOI
|
12 |
Lloyd P, Flesch G, Dieterle W. Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia 1994;35 Suppl 3:S10-3.
DOI
|
13 |
Benes J, Parada A, Figueiredo AA, Alves PC, Freitas AP, Learmonth DA, et al. Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives. J Med Chem 1999;42:2582-7.
DOI
|
14 |
Mattson RH, Cramer JA, Collins JF, Smith DB, Delgado-Escueta AV, Browne TR, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985;313:145-51.
DOI
|
15 |
Balon R, Berchou R. Hematologic side effects of psychotropic drugs. Psychosomatics 1986;27:119-20,125-7.
DOI
|
16 |
Moss RA. Drug-induced immune thrombocytopenia. Am J Hematol 1980;9:439-46.
DOI
|
17 |
Flanagan RJ, Dunk L. Haematological toxicity of drugs used in psychiatry. Hum Psychopharmacol 2008;23 Suppl 1:27-41.
DOI
|
18 |
Pisciotta AV. Drug-induced leukopenia and aplastic anemia. Clin Pharmacol Ther 1971;12:13-43.
DOI
|
19 |
Kaufman DW, Kelly JP, Anderson T, Harmon DC, Shapiro S. Evaluation of case reports of aplastic anemia among patients treated with felbamate. Epilepsia 1997;38:1265-9.
DOI
|
20 |
Pennell PB, Ogaily MS, Macdonald RL. Aplastic anemia in a patient receiving felbamate for complex partial seizures. Neurology 1995;45 (3 Pt 1):456-60.
DOI
|
21 |
Franceschi M, Ciboddo G, Truci G, Borri A, Canal N. Fatal aplastic anemia in a patient treated with carbamazepine. Epilepsia 1988;29: 582-3.
DOI
|